Zobrazeno 1 - 10
of 48
pro vyhledávání: '"Thomas H"'
Autor:
Kyu Hong, Peter S. Dragovich, Bing Zheng, Douglas D. Leipold, Thomas H. Pillow, Andrew Polson, Peter Yan, Shang-Fan Yu, Montserrat Carrasco-Triguero, Melissa Schutten, Geoffrey Del Rosario, Rebecca K. Rowntree, Fiona Zhong, Jack Sadowsky, Donna W. Lee, Helen Booler
Publikováno v:
Molecular Cancer Therapeutics. 20:340-346
We are interested in developing a second generation of antibody–drug conjugates (ADCs) for the treatment of non-Hodgkin lymphoma (NHL) that could provide a longer duration of response and be more effective in indolent NHL than the microtubule-inhib
Autor:
Lihong Zhang, Mizue Terai, Eduardo F. Farias, Julio A. Aguirre-Ghiso, Clinita E. Randolph, Naiming Zhou, Takami Sato, Timothy J. Purwin, Philip B. Wedegaertner, Andrew E. Aplin, Gregory G. Tall, Shihua Wu, Dougan McGrath, Thomas H. Charpentier, Dominic Lapadula, Jeffrey L. Benovic
Publikováno v:
Molecular Cancer Research. 17:963-973
Uveal melanoma is the most common intraocular tumor in adults and often metastasizes to the liver, leaving patients with few options. Recurrent activating mutations in the G proteins, Gαq and Gα11, are observed in approximately 93% of all uveal mel
Autor:
Ildiko Kovacs, Walter Berger, Frank Hilberg, Alexander Stiglbauer, Zsuzsanna Valko, Christine Pirker, Mir Alireza Hoda, Michael Grusch, Thomas Klikovits, Dora Lakatos, Andras Czirok, Balazs Dome, Judit Ozsvar, Thomas H. Helbich, Marion Gröger, József Tóvári, Balazs Hegedus, Viktoria Laszlo, Walter Klepetko, Tamás Garay
Publikováno v:
Clinical Cancer Research. 24:3729-3740
Purpose: Malignant pleural mesothelioma (MPM) is an aggressive thoracic tumor type with limited treatment options and poor prognosis. The angiokinase inhibitor nintedanib has shown promising activity in the LUME-Meso phase II MPM trial and thus is cu
Autor:
Aaron R. Folsom, Anna E. Prizment, Janet A. Tooze, Heather H. Nelson, Mara Z. Vitolins, Elizabeth A. Platz, Elizabeth Selvin, Thomas H. Mosley, John R. Barber, Kala Visvanathan, Corinne E. Joshu, Josef Coresh, David Couper, Kenneth R. Butler
Publikováno v:
Cancer Epidemiology, Biomarkers & Prevention. 27:295-305
Background: We describe the expansion of the Atherosclerosis Risk in Communities (ARIC) Study into a cancer cohort. In 1987 to 1989, ARIC recruited 15,792 participants 45 to 64 years old to be sex (55% female), race (27% black), and geographically di
Autor:
Wolf H. Fridman, Emily Chan, Elizabeth M. Jaffee, Christopher H. Lieu, S. Peter Kang, Michael A. Morse, Edward Cha, Neil H. Segal, Keavy E. McAbee, Nancy Roach, Cynthia L. Sears, Dung T. Le, Sharyn Worrall, Al B. Benson, Vanessa M Hubbard-Lucey, Dustin A. Deming, Andrea Dwyer, Anjelica Q. Davis Davis, Smitha S. Krishnamurthi, Jill O'Donnell-Tormey, Stanley R. Hamilton, Thomas H. Marsilje, Franck Housseau, Arthur Nathan Brodsky, Arvin Yang, Christopher R. Heery, Wells A. Messersmith, Richard M. Goldberg, Luis A. Diaz, Rebecca A. Moss
Publikováno v:
Cancer Immunology Research. 5:942-949
Immunotherapy is rapidly becoming a standard of care for many cancers. However, colorectal cancer had been generally resistant to immunotherapy, despite features in common with sensitive tumors. Observations of substantial clinical activity for check
Autor:
Lauren Fong, Brian Groff, Thomas H. Lee, John Goulding, Soheila Shirinbak, Ryan Bjordahl, Miguel Meza, Shohreh Sikaroodi, Cokey Nguyen, Moyar Q. Ge, Hui-Yi Chui, Robert Blum, Martin Hosking, Kai W. Wucherpfennig, Bryan Hancock, Lucas Ferrari de Andrade, Wen-I Yeh, Chia-Wei Chang, Bahram Valamehr, Janel Huffman, Joy Grant, Yijia Pan, Mochtar Pribadi, Thomas Dailey
Publikováno v:
Cancer Research. 81:1591-1591
Cancer immunotherapies have revolutionized cancer treatment by showing clinical efficacy across multiple cancer indications. However, tumor heterogeneity and evasion from host immune cell surveillance often limit the durability and efficacy of these
Autor:
Ravi Varadhan, Thomas H. Mosley, Josef Coresh, Alden L. Gross, Elizabeth A. Platz, Chinenye C. Ugoji, Corinne E. Joshu, Ron C. Hoogeveen, Christie M. Ballantyne, Anna E. Prizment, Lorraine T. Dean, A. Richey Sharrett, Keenan A. Walker, Adrienne Tin, Ken Butler
Publikováno v:
Cancer Research. 81:903-903
Background: Inflammation is hypothesized to underlie premature mortality in cancer survivors, yet little is known about the inflammatory proteins and pathways involved. Methods: 474 long-term (≥5 years) older adult survivors of prostate, breast, co
Autor:
KA Walker, Alden L. Gross, Elizabeth A. Platz, Chinenye C. Ugoji, A Tin, Thomas H. Mosley, A. R Sharrett, Kenneth R. Butler, Corinne E. Joshu, RC Hoogeveen, Lorraine T. Dean, Joseph Coresh, CM Ballantyne, Anna E. Prizment
Publikováno v:
Cancer Epidemiology, Biomarkers & Prevention. 30:802-802
Background Inflammation is linked to cognitive impairment (CI) in cancer survivors. But its role in survivors who develop dementia is unclear. Methods We evaluated dementia risk per log2 increase in 580 inflammatory proteins in 391 dementia-free long
Autor:
Erica L. Mayer, Michael Constantine, Thomas H. Openshaw, Anita Giobbie-Hurder, HJ Burstein, Meredith Faggen, S Come, Bryan P. Schneider, Nu Lin, J Walsh, Otto Metzger
Publikováno v:
Cancer Research. 77:P5-15
Background: Patient-reported outcomes (PROs) independently and directly describe patient (pt) treatment experiences, complement clinician reports, and are increasingly included in drug development. Eribulin (E) has activity in metastatic breast cance
Autor:
Robert Aiken, James A. Langford, Robert O. Dillman, Renato V. LaRocca, D. Bota, Krystal Carta, Adrienne M. Wang, Christopher Duma, Santosh Kesari, Jose Carrillo, Thomas H. Taylor, David Piccioni, Chris J. Langford, Robert T. O'Donnell, Gabriel Nistor, Candace Hsieh
Publikováno v:
Cancer Research. 80:CT182-CT182
Standard treatment of primary glioblastoma (GBM) is associated with poor survival. Adjunctive therapy with patient-specific vaccines may improve outcomes by inducing or enhancing each patient's anti-GBM immune response. A multi-institutional phase II